Hereditary diffuse gastric cancer

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
Tumor-associated macrophage, Research, Annual general meeting, Renal cell carcinoma, Hereditary diffuse gastric cancer, Head, Colorectal cancer, ESMO, Administration, Patient, Triple-negative breast cancer, ASCO, MSK, FDA, Lung cancer, G&A, Immunotherapy, Patent, ORR, Ovarian cancer, MPH, Cancer, Trial of the century, Diagnosis, Nivolumab, SITC, Operation, Antibody, Research and development, R, Congress, Orphan, Society, TNBC, ISAC, NSCLC, Pharmaceutical industry, Vaccine, Cryptocurrency

Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022.

Key Points: 
  • Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022.
  • Research and Development (R&D) Expenses – R&D expenses were $15.0 million for the quarter ended September 30, 2023, compared to $19.0 million for the same quarter in 2022.
  • General and Administrative (G&A) Expenses – G&A expenses were $5.8 million for the quarter ended September 30, 2023, compared to $5.5 million for the same quarter in 2022.
  • Loss from Operations – Loss from operations was $18.2 million for the quarter ended September 30, 2023, compared to $22.3 million for the same quarter in 2022.

MiNK Therapeutics Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 9, 2023
Hereditary diffuse gastric cancer, Survival, Periodic breathing, CGMP, NSCLC, Stomach, Inflammation, Cell, Memorial Sloan Kettering Cancer Center, Webcast, Canadian Aviation Regulations, Mink, TCR, Cancer, Autoimmunity, Therapy, Patient, HLA, Medical imaging, Pharmaceutical industry, Cryptocurrency

MiNK plans for expansion in autoimmune and inflammatory diseases.

Key Points: 
  • MiNK plans for expansion in autoimmune and inflammatory diseases.
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the third quarter 2023.
  • MiNK executives will host a conference call and webcast at 8:30 a.m.
  • We ended the third quarter with a cash balance of $6.4 million as compared to $10.6 million at June 30, 2023, and $19.6 million at December 31, 2022.

Triumvira Immunologics to Present New Clinical and Preclinical Data on its TAC-T Cell Technology at SITC 2023 Annual Meeting

Retrieved on: 
Monday, October 30, 2023
Neoplasm, Hereditary diffuse gastric cancer, Stomach, Therapy, Society for Immunotherapy of Cancer, HER2, TAC, Cell, GUCY2C, SITC, Immunotherapy, Annual general meeting, Safety, Society, Patient, Cancer, Vaccine, Reinsurance, Lobster

TAC01-HER2 is an innovative cell-based therapy that involves the utilization of genetically modified T cells derived from the patient themselves.

Key Points: 
  • TAC01-HER2 is an innovative cell-based therapy that involves the utilization of genetically modified T cells derived from the patient themselves.
  • These cells express a T-cell Antigen Coupler (TAC) which is designed to specifically recognize HER2 in tumors.
  • In addition to the TAC01-HER2 candidate, the company is investigating TAC-GUCY2C for the treatment of colorectal cancer and TAC01-CLDN18.2 for the treatment of pancreatic ductal adenocarcinoma and gastric cancer.
  • "Our commitment to developing innovative T cell therapeutics that harness the natural biology of T cells is supported by the promising preliminary results from our ongoing Phase I/II study targeting HER2 in solid tumors.

AI Medical Service Inc. Signs Joint Research Agreement with Leading Vietnamese Medical Institution

Retrieved on: 
Thursday, October 12, 2023
Technology, Health, Other Health, Professional Services, Artificial Intelligence, Oncology, Other Technology, Research, Medical Devices, Start-Up, General Health, Health Technology, Hardware, Science, Comment, Diagnosis, Multimedia, IGH, Prevalence, AI, File association, Death, Stomach, Hereditary diffuse gastric cancer, Cancer, AIM, Stomach cancer, Patient, Gastroenterology, Medical device

AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research agreement with Institute of Gastroenterology and Hepatology (hereinafter IGH) and will begin research activities on October 27, 2023.

Key Points: 
  • AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research agreement with Institute of Gastroenterology and Hepatology (hereinafter IGH) and will begin research activities on October 27, 2023.
  • AIM is the first Japanese company to sign a joint research agreement with IGH in the field of endoscopic AI, and IGH is the first Vietnamese institute that AIM has collaborated with thus far1.
  • Its collaboration with IGH will facilitate joint research designed to test the application of Japanese endoscopic AI in Vietnam.
  • Comment from CEO of AIM Tomohiro Tada, M.D., Ph.D.
    "I am very pleased that we have established a joint research agreement with IGH, one of the leading research institutes in Vietnam.

The SparX Group Enters into a Collaboration with Arovella Therapeutics for the Development of CLDN18.2-CAR-iNKT Cell Therapy

Retrieved on: 
Tuesday, October 10, 2023
Partnership, Sparx, ASX, SPARX Group, Cell, Therapy, Myeloid-derived suppressor cell, Cytokine release syndrome, Mab, Safety, Hereditary diffuse gastric cancer, Tumor-associated macrophage, GC, MDSC, CD1D, Cancer, Tams, Fatality, Vaccine, Pharmaceutical industry

Dr. Gui-Dong Zhu, CEO of the SparX Group, elucidated on the significance of this collaboration: "Our partnership with Arovella represents a transformative phase in advancing mAb-based therapies.

Key Points: 
  • Dr. Gui-Dong Zhu, CEO of the SparX Group, elucidated on the significance of this collaboration: "Our partnership with Arovella represents a transformative phase in advancing mAb-based therapies.
  • Invariant Natural Killer T (iNKT) cells, distinguished by their recognition of lipid antigens via the CD1d molecule, have emerged as potent therapeutic vectors.
  • We profoundly acknowledge CLDN 18.2-iNKT cell therapy as a groundbreaking paradigm in oncological therapeutics."
  • The pathological architecture of tumor development often exposes the CLDN18.2, rendering it accessible to novel treatments such as CAR-iNKT cell therapies.

STOPTOBER: Nearly 6 in 10 British Doctors Mistakenly Believe Nicotine Causes Lung Cancer, Endangering Efforts to Help More Than Six Million Brits Quit

Retrieved on: 
Tuesday, October 3, 2023
Smoke, COPD, Learning, Smoker, Smoking, Nicotine, Hereditary diffuse gastric cancer, Doctor, Cancer, Lung cancer, Herbal cigarette, Bladder cancer, Head, Neck, Atherosclerosis, UK Government Decontamination Service, Government, Science Publishing Group, Patient, Physician, NHS, Death, Tobacco, Nursing, Health

LONDON, Oct. 3, 2023 /PRNewswire/ -- Nearly 6 in 10 doctors in the UK mistakenly attribute negative health consequences of smoking to nicotine, directly jeopardising efforts made in helping smokers quit, a survey funded by a Foundation for a Smoke-Free World grant has found.

Key Points: 
  • 60% of British doctors on average incorrectly believe nicotine causes both lung cancer and 65% believe it causes atherosclerosis.
  • 1 in 2 UK doctors says they are not appropriately trained to help patients quit smoking.
  • The misconception about the dangers of nicotine among British doctors leaves 60% believing it directly causes lung cancer.
  • A similar number (59%) mistakenly believe nicotine causes head, neck, and gastric cancers and 56% say it causes bladder cancer.

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

Retrieved on: 
Thursday, September 28, 2023
Hereditary diffuse gastric cancer, Cancer, Immunotherapy, Endometrial cancer, ISAC, Patient, Diagnosis, Rare, FDA, Stomach, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancers

Key Points: 
  • BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancers
    The FDA granted BDC-1001 Orphan Drug Designation for the treatment of gastric cancer, including gastroesophageal junction cancer
    REDWOOD CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for BDC-1001 for the treatment of gastric cancer, including gastroesophageal junction cancer.
  • “Receiving Orphan Drug Designation from the FDA is an important step forward in the development of BDC-1001 and reinforces the potential of BDC-1001 to address unmet needs for patients with gastric cancers,” said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics.
  • In addition to gastric cancer, we are also evaluating BDC-1001 in three other tumor types with significant unmet medical need: HER2-positive breast, colorectal, and endometrial cancers.
  • The designation affords Bolt the potential for certain benefits, including up to seven years of post-approval market exclusivity, assistance in the drug development process, tax credits for clinical development, and exemptions from certain FDA fees.

Biomerica Reports Fiscal 2023 Year End Results

Retrieved on: 
Friday, August 25, 2023
SAB, Migraine, Osteoarthritis, Helicobacter pylori, LDT, Mayo Clinic, CRC, Hereditary diffuse gastric cancer, The American Journal of Gastroenterology, Intellectual property, EZ, Clinical and Translational Gastroenterology, COVID-19, CVS, Coronavirus Scientific Advisory Board, Completeness, Large intestine, Ulcerative colitis, Gastroesophageal reflux disease, Colorectal cancer, CLIA, American Journal, Phlebotomy, Patient, Physician, IBS, National accounts, Rome, FDA, Stomach, Pharmaceutical industry, Walmart, Gastroenterology

Net sales for the fiscal year ended May 31, 2023 were $5.3 million as compared to net sales of $18.9 million in fiscal 2022.

Key Points: 
  • Net sales for the fiscal year ended May 31, 2023 were $5.3 million as compared to net sales of $18.9 million in fiscal 2022.
  • Net loss was $7.1 million for fiscal 2023 compared to a net loss of $4.6 million for fiscal 2022.
  • The decrease in sales for fiscal 2023 was related to the Company’s decrease in sales of COVID-19 antigen tests in fiscal 2023 compared to the prior fiscal year.
  • Sales revenues excluding Covid test sales increased by 15% for fiscal 2023 compared to fiscal 2022.

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
Tuesday, August 22, 2023
DNA, Cell biology, Methylation, MBio, Hereditary diffuse gastric cancer, Collaborative writing, Cone Health Women's Hospital, Culture, Wistar, Infection, Cancer, Biomedical Research, Epstein–Barr virus, Research, Gene expression, Cell, T32, National Institutes of Health, Bangladesh Technical Education Board, Harvard Medical School, Ellen, Cytosine, Coriell Institute for Medical Research, Genome, Epigenome, Wistar Institute, Tempera, Hospital, DNA methylation, Stomach, P30, NIH, Medical research, EBV, Vaccine, Pharmaceutical industry, Decitabine, Brigham

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
Tuesday, August 22, 2023
DNA, Cell biology, Methylation, MBio, Hereditary diffuse gastric cancer, Collaborative writing, Cone Health Women's Hospital, Culture, Wistar, Infection, Cancer, Biomedical Research, Epstein–Barr virus, Research, Gene expression, Cell, T32, National Institutes of Health, Bangladesh Technical Education Board, Harvard Medical School, Ellen, Cytosine, Coriell Institute for Medical Research, Genome, Epigenome, Wistar Institute, Tempera, Hospital, DNA methylation, Stomach, P30, NIH, Medical research, EBV, Vaccine, Pharmaceutical industry, Decitabine, Brigham

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.